Oxford BioMedica plc · LSE:OXB
Oxford BioMedica — Shareholder Meeting (May 2017)
18 slides from Oxford BioMedica's shareholder meeting presentation, May 23, 2017
Slide 1: A LentiVector Platform Company, and a leader in gene and cell therapy
A LentiVector® Platform Company, and a leader in gene and cell therapy Annual General Meeting 23 May 2017
Slide 2: Forward-looking statements
Forward-looking statements This presentation does not constitute an offer to sell or a solicitation of offers to buy Ordinary Shares (the “Securities”). Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions 2 Cohort expressed
Slide 3: Strategy: Leveraging Our LentiVector Delivery Platform
Strategy: Leveraging Our LentiVector® Delivery Platform Partners’ Programmes OXB products via spin out or Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) out-licence 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% • Process developmentMax.fees up t
Slide 4: Operational highlights (1 of 2)
Operational highlights (1 of 2) • Strong progress from LentiVector® delivery platform and cell therapy partnerships Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) • 1, n=3 Novartis 1xcollaboration Original progressing well 27% CTL019 Mean with Max. up to
Slide 5: Operational highlights (2 of 2)
Operational highlights (2 of 2) • State-of-the-art bioprocessing and laboratory facilities • Cohort2 Major capacity Dose expansion completed3 months (UPDRS) Administration 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% • MHRA approval granted f
Slide 6: Partnering
Partnering
Slide 7: Oxford BioMedica is a leader in lentiviral vector technology
Oxford BioMedica is a leader in lentiviral vector technology • Gene and cell therapy field set to grow into $ multi-billion sector over next 5-10 years. 2 Cohort Dose Administration Several products, particularly ex vivo, 3likely months (UPDRS) to 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n
Slide 8: Financial impact of growing Partnership activities
Financial impact of growing Partnership activities Gross income(1) (£m) Partnering segment (£m) 35 2015 2016 30 2 Cohort Dose Administration 30 Licences, 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 25 Original incentives, Mean 27% 30% Mean 29% Mean 20% 1, n=3 1x grants Max. up t
Slide 9: Products
Products
Slide 10: Products Pipeline - Proprietary and Partnered
Products Pipeline - Proprietary and Partnered Product Indication Pre-Clinical Phase I Phase I/II Phase II Phase III Approval OXB Proprietary Products OXB-102 Cohort2 Parkinson’s Dose disease Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) OXB-202 1, n=3 Corneal 1xgraf
Slide 11: In-House Programmes
In-House Programmes • OXB-102 (Parkinson’s disease) • OXB-101 showed encouraging efficacy and long-term duration of benefit Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) • OXB-102 in late-stage preparations for 1, n=3 1x Original Mean 27% Mean 30% Mean
Slide 12: Partners' programmes
Partners’ programmes • Novartis CTL019 • BLA for r/r ALL accepted by FDA (March 2017),granted priority review Cohort • 2 NovartisDose plan to file in EU in late 2017 3 months (UPDRS) Administration 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) USD Millions 1, n=3• DLBCL 1xgranted FDA Breakthrough
Slide 13: Oxford
Oxford
Slide 14: Innovation and optimisation to build long-term value
Proprietary R&D Activity In-house Product Discovery/Research – Technical developments – continuous improvement of the LentiVector ® (UPDRS) providing a flow of new product 2 Cohort Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years 1, n=3 1x Original Mean 27% platform Mean
Slide 15: Summary
Summary
Slide 16: Potential catalysts over next 12 months
Potential catalysts over next 12 months • Novartis progress Cohort2 • Data Dose from adult r/r Administration DLBCL study3 (expected months (UPDRS) Q26 months 2017) (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 27% Mean 30% Mean 29% Mean 20% 1, n=3 • 1x Confirmation commercialMean Original of OXB supply Ma
Slide 17: Summary: A Leading Gene and Cell Therapy Company
Summary: A Leading Gene and Cell Therapy Company • Gene and cell therapy is predicted to grow into a multi-billion US$ sector Cohort2 Dose 1 over the next 5-10 Administration years 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20%
Slide 18: Contact Us
Contact Us Oxford BioMedica plc Windrush Court Transport Way Oxford OX4 6LT John Dawson, CEO Tim Watts, CFO Tel: +44 (0) 1865 783 000 enquiries@oxfordbiomedica.co.uk www.oxfordbiomedica.co.uk